Healthcare - Biotechnology - NASDAQ - US
$ 2.84
-5.8 %
$ 326 M
Market Cap
-3.05
P/E
CASH FLOW STATEMENT
-64.6 M
OPERATING CASH FLOW
81.9 M
INVESTING CASH FLOW
-4.48 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Absci Corporation
| Net Income | -111 M |
| Depreciation & Amortization | 14 M |
| Capital Expenditures | -860 K |
| Stock-Based Compensation | 11.4 M |
| Change in Working Capital | 1.52 M |
| Others | 21.4 M |
| Free Cash Flow | -65.5 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | |
|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||
| Net Income | (110.6) | (104.9) | (101.0) | (14.4) | (6.6) |
| Depreciation & Amortization | 14.0 | 13.0 | 6.7 | 1.1 | 0.5 |
| Deferred Income Tax | 52 K | (0.5) | (8.9) | 0 | 0 |
| Stock Based Compensation | 11.4 | 12.5 | 10.6 | 0.4 | 42 K |
| Other Operating Activities | 19.1 | 33 K | 35.1 | 0.8 | 0.1 |
| Change in Working Capital | 1.5 | (1.5) | (3.1) | 1.0 | 89 K |
| Cash From Operations | (64.6) | (81.3) | (60.6) | (11.0) | (6.0) |
| INVESTING CASH FLOW | |||||
| Capital Expenditures | (0.9) | (16.2) | (38.0) | (2.2) | (1.1) |
| Other Items | 82.8 | (110.8) | (29.3) | 10 K | 9 K |
| Cash From Investing Activities | 81.9 | (127.0) | (67.4) | (2.2) | (1.1) |
| FINANCING CASH FLOW | |||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | (5.3) | 4.6 | 120.9 | 1.6 | 2.4 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 4.9 | 69.3 | 10.3 |
| Cash From Financing Activities | (4.5) | 5.2 | 336.2 | 71.0 | 12.7 |
| CHANGE IN CASH | |||||
| Net Change In Cash | 12.8 | (203.1) | 208.2 | 57.8 | 5.6 |
| FREE CASH FLOW | |||||
| Free Cash Flow | (65.5) | (97.5) | (98.6) | (13.2) | (7.1) |